Ipsen has just announced the appointment of Philippe Lopes-Fernandes as Executive Vice-President, Chief Business Officer, effective October 1, 2020. Based in Cambridge (Massachusetts, United States), he will be responsible for all business development and partnership management.He will report directly to David Loew, CEO of Ipsen, and will be a member of the Executive Leadership Team.“As Chief Business Officer of Ipsen, Philippe will play a crucial role in our external innovation strategy.The members of the Executive Leadership Team and I are delighted to welcome him to the team and to work alongside him.His exceptional experience in international business development, his excellent reputation and his ability to work closely with the scientific community around the world will make him a considerable asset in our efforts to develop our position as a world biopharmaceutical leader through external innovation.Philippe will make a major contribution to our strong network of partnerships and will be of great help in strengthening our product portfolio in R&D,” said David Loew, CEO of Ipsen.“I am very happy to join Ipsen at such a decisive moment for the Group,” said Philippe Lopes-Fernandes.“I look forward to working with David, the ELT and the Business Development team to strengthen Ipsen's agreements in its therapeutic areas, and thus contribute to realizing our vision of bringing solutions to patients with important needs. unsatisfied doctors.»Before joining Ipsen, Philippe worked at Merck KGaA where he became Senior Vice President, Global Director of Business Development and Partnership Management, based in Cambridge (USA).Previously, he held several positions at Merck KGaA, in Business Development, Mergers and Acquisitions, Finance and Marketing in France, Portugal, Germany, Switzerland and the United States.Philippe graduated from the Institut Supérieur de Gestion (ISG) in Paris in 1994. He is a Foreign Trade Advisor for France and a member of the Board of Directors of several companies.He will remain based in Cambridge (USA).Share the post "Ipsen: Philippe Lopes-Fernandes appointed Executive Vice-President, Chief Business Officer"Roche France and the University Hospital of Brest are joining forces with the startup Octopize-Mimethik Data for the ethical use of health data thanks to its anonymization technology to stimulate a new dynamic around the "secure sharing of health data", in as part of the Coalition Next call for projects.Acticor Biotech, a clinical-stage biotechnology company specializing in the development of innovative drugs for the treatment of cardiovascular emergencies, in particular stroke, announced that it has received PRIority Medicines (PRIME) status from the European Medicines Agency (EMA) for its drug candidate, glenzocimab, in the treatment of patients with stroke.GeNeuro announced the publication in the leading scientific journal “Annals of Neurology” of the results of the collaboration between GeNeuro and the National Institute of Neurological Disorders and Stroke (NINDS).NINDS is part of the US National Institutes of Health (NIH).This publication describes the new pathogenic mechanism of HERV-K in sporadic ALS and confirms the action of the GeNeuro antibody to neutralize this toxicity.The Novasep‐PharmaZell Group has announced an investment of €7.3 million at its Mourenx site (64 - France), as part of a global project supported by the Plan France Relance, to create a multi-purpose pilot workshop within one of its production units.This new industrial tool aims to support the growth of the Mourenx site and to support demand for the production of active pharmaceutical ingredients (API), in particular those with high therapeutic activity (HPAPI) for the treatment of cancer.Innate Pharma announced that Sanofi has made the decision to advance IPH6401/SAR'514 into regulatory preclinical studies for investigation of an investigational new drug, triggering a €3 million milestone payment from Sanofi to Innate .Crossject, a "specialty pharma" which will soon develop and market a portfolio of drugs dedicated to emergency situations, has announced the end of the phase of injections carried out as part of the bioequivalence clinical study for ZENEO® Midazolam.Medesis Pharma, a pharmaceutical biotechnology company developing drug candidates based on its proprietary Aonys® technology for administering active ingredients in nano micelles by oral route, announced the decision of AFM-Téléthon to participate up to 300,000 euros over 24 months to contribute to the early stages of preclinical development of its treatment for Huntington's disease.Every Monday, our free newsletter